메뉴 건너뛰기




Volumn 2016, Issue , 2016, Pages

State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS C VACCINE;

EID: 84994410011     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2016/1412840     Document Type: Review
Times cited : (11)

References (182)
  • 1
    • 79958780802 scopus 로고    scopus 로고
    • Perspective: Test and treat this silent killer
    • B. R. Edlin, "Perspective: Test and treat this silent killer, " Nature, vol. 474, no. 7350, pp. S18-S19, 2011.
    • (2011) Nature , vol.474 , Issue.7350 , pp. S18-S19
    • Edlin, B.R.1
  • 2
    • 84901838719 scopus 로고    scopus 로고
    • Center for Disease Control and Prevention (CDC)
    • Center for Disease Control and Prevention (CDC), "Surveillance for Viral Hepatitis-United States, " 2013, http://www. cdc. gov/hepatitis/statistics/2013surveillance/commentary. htm#hepatitisC.
    • (2013) Surveillance for Viral Hepatitis-United States
  • 3
    • 84914150658 scopus 로고    scopus 로고
    • Global epidemiology and genotype distribution of the hepatitis C virus infection
    • E. Gower, C. Estes, S. Blach, K. Razavi-Shearer, and H. Razavi, "Global epidemiology and genotype distribution of the hepatitis C virus infection, " Journal of Hepatology, vol. 61, no. 1, pp. S45-S57, 2014.
    • (2014) Journal of Hepatology , vol.61 , Issue.1 , pp. S45-S57
    • Gower, E.1    Estes, C.2    Blach, S.3    Razavi-Shearer, K.4    Razavi, H.5
  • 4
    • 84903643207 scopus 로고    scopus 로고
    • Hepatitis C worldwide and in Brazil: Silent epidemic-data on disease including incidence, transmission, prevention, and treatment
    • I. F. Kretzer, A. do Livramento, J. da Cunha et al., "Hepatitis C worldwide and in Brazil: silent epidemic-data on disease including incidence, transmission, prevention, and treatment, " The Scientific World Journal, vol. 2014, Article ID 827849, 10 pages, 2014.
    • (2014) The Scientific World Journal , vol.2014
    • Kretzer, I.F.1    Do Livramento, A.2    Da Cunha, J.3
  • 5
    • 84894634227 scopus 로고    scopus 로고
    • The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection
    • J. Grebely, K. Page, R. Sacks-Davis et al., "The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection, " Hepatology, vol. 59, no. 1, pp. 109-120, 2014.
    • (2014) Hepatology , vol.59 , Issue.1 , pp. 109-120
    • Grebely, J.1    Page, K.2    Sacks-Davis, R.3
  • 6
    • 49649118223 scopus 로고    scopus 로고
    • Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression
    • H.-H. Thein, Q. Yi, G. J. Dore, and M. D. Krahn, "Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression, " Hepatology, vol. 48, no. 2, pp. 418-431, 2008.
    • (2008) Hepatology , vol.48 , Issue.2 , pp. 418-431
    • Thein, H.-H.1    Yi, Q.2    Dore, G.J.3    Krahn, M.D.4
  • 7
    • 84871036375 scopus 로고    scopus 로고
    • Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010
    • R. Lozano, M. Naghavi, K. Foreman et al., "Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010, " The Lancet, vol. 380, no. 9859, pp. 2095-2128, 2012.
    • (2012) The Lancet , vol.380 , Issue.9859 , pp. 2095-2128
    • Lozano, R.1    Naghavi, M.2    Foreman, K.3
  • 8
    • 84880301028 scopus 로고    scopus 로고
    • Current progress in development of hepatitis C virus vaccines
    • T. J. Liang, "Current progress in development of hepatitis C virus vaccines, " Nature Medicine, vol. 19, no. 7, pp. 869-878, 2013.
    • (2013) Nature Medicine , vol.19 , Issue.7 , pp. 869-878
    • Liang, T.J.1
  • 10
    • 84952837127 scopus 로고    scopus 로고
    • Universal screening for chronic hepatitis C virus
    • M. L. Shiffman, "Universal screening for chronic hepatitis C virus, " Liver International, vol. 36, no. S1, pp. 62-66, 2016.
    • (2016) Liver International , vol.36 , Issue.S1 , pp. 62-66
    • Shiffman, M.L.1
  • 11
    • 84986290313 scopus 로고    scopus 로고
    • 2014 French guidelines for hepatitis B and C screening. A combined targeted andmass testing strategy of chronic viruses namely HBV, HCV and HIV
    • J. Bottero, C. Brouard, F. Roudot-Thoraval et al., "2014 French guidelines for hepatitis B and C screening. A combined targeted andmass testing strategy of chronic viruses namely HBV, HCV and HIV, " Liver International, vol. 36, no. 10, pp. 1442-1449, 2016.
    • (2016) Liver International , vol.36 , Issue.10 , pp. 1442-1449
    • Bottero, J.1    Brouard, C.2    Roudot-Thoraval, F.3
  • 12
    • 84963960484 scopus 로고    scopus 로고
    • HIV and hepatitis testing: Global progress, challenges, and future directions
    • P. Easterbrook, C. Johnson, C. Figueroa, and R. Baggaley, "HIV and hepatitis testing: global progress, challenges, and future directions, " AIDS Reviews, vol. 18, no. 1, pp. 3-14, 2016.
    • (2016) AIDS Reviews , vol.18 , Issue.1 , pp. 3-14
    • Easterbrook, P.1    Johnson, C.2    Figueroa, C.3    Baggaley, R.4
  • 13
    • 84861575412 scopus 로고    scopus 로고
    • Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008
    • M. M. Denniston, R. M. Klevens, G. M. McQuillan, and R. B. Jiles, "Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008, " Hepatology, vol. 55, no. 6, pp. 1652-1661, 2012.
    • (2012) Hepatology , vol.55 , Issue.6 , pp. 1652-1661
    • Denniston, M.M.1    Klevens, R.M.2    McQuillan, G.M.3    Jiles, R.B.4
  • 14
    • 0004016899 scopus 로고    scopus 로고
    • World Health Organization, Fact Sheet 164, World Health Organization, Geneva, Switzerland
    • World Health Organization, "Hepatitis C, " Fact Sheet 164, World Health Organization, Geneva, Switzerland, 2015, http:// www. who. int/mediacentre/factsheets/fs164/en/.
    • (2015) Hepatitis C
  • 19
    • 84930398412 scopus 로고    scopus 로고
    • Hepatitis C virus: Virology, diagnosis and treatment
    • H. C. Li and S. Y. Lo, "Hepatitis C virus: virology, diagnosis and treatment, " World Journal of Hepatology, vol. 7, no. 10, pp. 1377-1389, 2015.
    • (2015) World Journal of Hepatology , vol.7 , Issue.10 , pp. 1377-1389
    • Li, H.C.1    Lo, S.Y.2
  • 20
    • 84912098460 scopus 로고    scopus 로고
    • Diagnostic tests for hepatitis C: Recent trends in electrochemical immunosensor and genosensor analysis
    • C. V. Uliana, C. S. Riccardi, andH. Yamanaka, "Diagnostic tests for hepatitis C: recent trends in electrochemical immunosensor and genosensor analysis, " World Journal of Gastroenterology, vol. 20, no. 42, pp. 15476-15491, 2014.
    • (2014) World Journal of Gastroenterology , vol.20 , Issue.42 , pp. 15476-15491
    • Uliana, C.V.1    Riccardi, C.S.2    Yamanaka, H.3
  • 21
    • 33646270395 scopus 로고    scopus 로고
    • Hepatitis C virus serologic and virologic tests and clinical diagnosis of HCV-related liver disease
    • S. Chevaliez and J.-M. Pawlotsky, "Hepatitis C virus serologic and virologic tests and clinical diagnosis of HCV-related liver disease, " International Journal of Medical Sciences, vol. 3, no. 2, pp. 35-40, 2006.
    • (2006) International Journal of Medical Sciences , vol.3 , Issue.2 , pp. 35-40
    • Chevaliez, S.1    Pawlotsky, J.-M.2
  • 22
    • 79955681183 scopus 로고    scopus 로고
    • Multicenter evaluation of a fully automated third-generation anti-HCV antibody screening test with excellent sensitivity and specificity
    • F. Alborino, A. Burighel, F.-W. Tiller et al., "Multicenter evaluation of a fully automated third-generation anti-HCV antibody screening test with excellent sensitivity and specificity, " Medical Microbiology and Immunology, vol. 200, no. 2, pp. 77-83, 2011.
    • (2011) Medical Microbiology and Immunology , vol.200 , Issue.2 , pp. 77-83
    • Alborino, F.1    Burighel, A.2    Tiller, F.-W.3
  • 23
    • 0035076670 scopus 로고    scopus 로고
    • Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: An analysis of the literature
    • C. Colin, D. Lanoir, S. Touzet, L. Meyaud-Kraemer, F. Bailly, and C. Trepo, "Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: An analysis of the literature, " Journal of Viral Hepatitis, vol. 8, no. 2, pp. 87-95, 2001.
    • (2001) Journal of Viral Hepatitis , vol.8 , Issue.2 , pp. 87-95
    • Colin, C.1    Lanoir, D.2    Touzet, S.3    Meyaud-Kraemer, L.4    Bailly, F.5    Trepo, C.6
  • 24
    • 0028795676 scopus 로고
    • Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA
    • J. M. Barrera, B. Francis, G. Ercilla et al., "Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA, " Vox Sanguinis, vol. 68, no. 1, pp. 15-18, 1995.
    • (1995) Vox Sanguinis , vol.68 , Issue.1 , pp. 15-18
    • Barrera, J.M.1    Francis, B.2    Ercilla, G.3
  • 25
    • 84861334032 scopus 로고    scopus 로고
    • NASPGHAN Practice guidelines: Diagnosis and management of hepatitis c infection in infants, children, and adolescents
    • C. L. Mack, R. P. Gonzalez-Peralta, N. Gupta et al., "NASPGHAN Practice guidelines: diagnosis and management of hepatitis c infection in infants, children, and adolescents, " Journal of Pediatric Gastroenterology and Nutrition, vol. 54, no. 6, pp. 838-855, 2012.
    • (2012) Journal of Pediatric Gastroenterology and Nutrition , vol.54 , Issue.6 , pp. 838-855
    • Mack, C.L.1    Gonzalez-Peralta, R.P.2    Gupta, N.3
  • 26
    • 80055096809 scopus 로고    scopus 로고
    • HepatitisCvirus core antigen: Analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay
    • M. C. Medici, G. Furlini, A. Rodella et al., "HepatitisCvirus core antigen: Analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay, " Journal of Clinical Virology, vol. 51, no. 4, pp. 264-269, 2011.
    • (2011) Journal of Clinical Virology , vol.51 , Issue.4 , pp. 264-269
    • Medici, M.C.1    Furlini, G.2    Rodella, A.3
  • 27
    • 84924935494 scopus 로고    scopus 로고
    • Hepatitis C core antigen testing: A reliable, quick, and potentially cost-effective alternative to hepatitis C polymerase chain reaction in diagnosing acute hepatitis C virus infection
    • F. V. Cresswell, M. Fisher, D. J. Hughes, S. G. Shaw, G. Homer, and M. O. Hassan-Ibrahim, "Hepatitis C core antigen testing: A reliable, quick, and potentially cost-effective alternative to hepatitis C polymerase chain reaction in diagnosing acute hepatitis C virus infection, " Clinical Infectious Diseases, vol. 60, no. 2, pp. 263-266, 2015.
    • (2015) Clinical Infectious Diseases , vol.60 , Issue.2 , pp. 263-266
    • Cresswell, F.V.1    Fisher, M.2    Hughes, D.J.3    Shaw, S.G.4    Homer, G.5    Hassan-Ibrahim, M.O.6
  • 28
    • 84870405295 scopus 로고    scopus 로고
    • Hepatitis C virus testing of persons born during 1945-1965: Recommendations from the centers for disease control and prevention
    • B. D. Smith, R. L. Morgan, G. A. Beckett, Y. Falck-Ytter, D. Holtzman, and J. W. Ward, "Hepatitis C virus testing of persons born during 1945-1965: recommendations from the centers for disease control and prevention, " Annals of Internal Medicine, vol. 157, no. 11, pp. 817-822, 2012.
    • (2012) Annals of Internal Medicine , vol.157 , Issue.11 , pp. 817-822
    • Smith, B.D.1    Morgan, R.L.2    Beckett, G.A.3    Falck-Ytter, Y.4    Holtzman, D.5    Ward, J.W.6
  • 30
    • 84868333689 scopus 로고    scopus 로고
    • Accuracy of rapid and point-of-care screening tests for hepatitis C: A systematic review and meta-analysis
    • S. Shivkumar, R. Peeling, Y. Jafari, L. Joseph, and N. Pant Pai, "Accuracy of rapid and point-of-care screening tests for hepatitis C: A systematic review and meta-analysis, " Annals of Internal Medicine, vol. 157, no. 8, pp. 558-566, 2012.
    • (2012) Annals of Internal Medicine , vol.157 , Issue.8 , pp. 558-566
    • Shivkumar, S.1    Peeling, R.2    Jafari, Y.3    Joseph, L.4    Pant Pai, N.5
  • 31
    • 84902164210 scopus 로고    scopus 로고
    • Performance of rapid hepatitis C virus antibody assays among high-and lowrisk populations
    • L. D. P. Scalioni, H. M. Cruz, V. S. de Paula et al., "Performance of rapid hepatitis C virus antibody assays among high-and lowrisk populations, " Journal of Clinical Virology, vol. 60, no. 3, pp. 200-205, 2014.
    • (2014) Journal of Clinical Virology , vol.60 , Issue.3 , pp. 200-205
    • Scalioni, L.D.P.1    Cruz, H.M.2    De Paula, V.S.3
  • 32
    • 84926290284 scopus 로고    scopus 로고
    • Diagnostic accuracy of point-of-care tests for hepatitis C virus infection: A systematic review and meta-analysis
    • M. S. Khuroo, N. S. Khuroo, and M. S. Khuroo, "Diagnostic accuracy of point-of-care tests for hepatitis C virus infection: A systematic review and meta-analysis, " PLoS ONE, vol. 10, no. 3, Article ID e0121450, 2015.
    • (2015) PLoS ONE , vol.10 , Issue.3
    • Khuroo, M.S.1    Khuroo, N.S.2    Khuroo, M.S.3
  • 34
    • 84867288022 scopus 로고    scopus 로고
    • Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965
    • Centers for Disease Control and Prevention (CDC)
    • Centers for Disease Control and Prevention (CDC), "Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965, " Morbidity and Mortality Weekly Report (MMWR), vol. 61, no. RR04, pp. 1-32, 2012, http://www. cdc. gov/mmwr/pdf/rr/rr6104. pdf.
    • (2012) Morbidity and Mortality Weekly Report (MMWR) , vol.61 , Issue.RR04 , pp. 1-32
  • 35
    • 84939653819 scopus 로고    scopus 로고
    • Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus
    • AASLD/IDSA HCV Guidance Panel
    • AASLD/IDSA HCV Guidance Panel, "Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus, " Hepatology, vol. 62, no. 3, pp. 932-954, 2015.
    • (2015) Hepatology , vol.62 , Issue.3 , pp. 932-954
  • 36
    • 84867288022 scopus 로고    scopus 로고
    • Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965
    • B. D. Smith, R. L. Morgan, G. A. Beckett et al., "Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965, " MMWR Recommendations and Reports, vol. 61, no. 4, pp. 1-32, 2012.
    • (2012) MMWR Recommendations and Reports , vol.61 , Issue.4 , pp. 1-32
    • Smith, B.D.1    Morgan, R.L.2    Beckett, G.A.3
  • 37
    • 84881147288 scopus 로고    scopus 로고
    • Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: U. S. Preventive Services Task Force recommendation statement
    • V. A. Moyer, "Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: U. S. Preventive Services Task Force recommendation statement, " Annals of Internal Medicine, vol. 159, no. 3, pp. 210-218, 2013.
    • (2013) Annals of Internal Medicine , vol.159 , Issue.3 , pp. 210-218
    • Moyer, V.A.1
  • 38
    • 0035726250 scopus 로고    scopus 로고
    • Management of hepatitis C patients by primary care physicians in the USA: Results of a national survey
    • T. M. Shehab, S. S. Sonnad, and A. S. F. Lok, "Management of hepatitis C patients by primary care physicians in the USA: results of a national survey, " Journal of Viral Hepatitis, vol. 8, no. 5, pp. 377-383, 2001.
    • (2001) Journal of Viral Hepatitis , vol.8 , Issue.5 , pp. 377-383
    • Shehab, T.M.1    Sonnad, S.S.2    Lok, A.S.F.3
  • 39
    • 0037345681 scopus 로고    scopus 로고
    • Identification and management of hepatitis C patients in primary care clinics
    • T. M. Shehab, M. Orrego, R. Chunduri, and A. S. F. Lok, "Identification and management of hepatitis C patients in primary care clinics, "The American Journal of Gastroenterology, vol. 98, no. 3, pp. 639-644, 2003.
    • (2003) The American Journal of Gastroenterology , vol.98 , Issue.3 , pp. 639-644
    • Shehab, T.M.1    Orrego, M.2    Chunduri, R.3    Lok, A.S.F.4
  • 40
    • 84880172886 scopus 로고    scopus 로고
    • Indications for testing among reported cases of HCV infection from enhanced hepatitis surveillance sites in the United States, 2004-2010
    • R. Mahajan, S. J. Liu, R. M. Klevens, and S. D. Holmberg, "Indications for testing among reported cases of HCV infection from enhanced hepatitis surveillance sites in the United States, 2004-2010, " American Journal of Public Health, vol. 103, no. 8, pp. 1445-1449, 2013.
    • (2013) American Journal of Public Health , vol.103 , Issue.8 , pp. 1445-1449
    • Mahajan, R.1    Liu, S.J.2    Klevens, R.M.3    Holmberg, S.D.4
  • 41
    • 84876675062 scopus 로고    scopus 로고
    • Electronic messages increase hepatitis B screening in at-risk Asian American patients: A randomized, controlled trial
    • L. Hsu, C. L. Bowlus, S. L. Stewart et al., "Electronic messages increase hepatitis B screening in at-risk Asian American patients: A randomized, controlled trial, " Digestive Diseases and Sciences, vol. 58, no. 3, pp. 807-814, 2013.
    • (2013) Digestive Diseases and Sciences , vol.58 , Issue.3 , pp. 807-814
    • Hsu, L.1    Bowlus, C.L.2    Stewart, S.L.3
  • 42
    • 84923486405 scopus 로고    scopus 로고
    • Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department
    • J. W. Galbraith, R. A. Franco, J. P. Donnelly et al., "Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department, " Hepatology, vol. 61, no. 3, pp. 776-782, 2015.
    • (2015) Hepatology , vol.61 , Issue.3 , pp. 776-782
    • Galbraith, J.W.1    Franco, R.A.2    Donnelly, J.P.3
  • 43
    • 84938211526 scopus 로고    scopus 로고
    • Implementing hospital-based baby boomer hepatitis C virus screening and linkage to care: Strategies, results, and costs
    • B. J. Turner, B. S. Taylor, J. T. Hanson et al., "Implementing hospital-based baby boomer hepatitis C virus screening and linkage to care: strategies, results, and costs, " Journal of Hospital Medicine, vol. 10, no. 8, pp. 510-516, 2015.
    • (2015) Journal of Hospital Medicine , vol.10 , Issue.8 , pp. 510-516
    • Turner, B.J.1    Taylor, B.S.2    Hanson, J.T.3
  • 44
    • 84878930046 scopus 로고    scopus 로고
    • Birth cohort screening for chronic hepatitis during colonoscopy appointments
    • D. M. Sears, D. C. Cohen, K. Ackerman, J. E. Ma, and J. Song, "Birth cohort screening for chronic hepatitis during colonoscopy appointments, " American Journal of Gastroenterology, vol. 108, no. 6, pp. 981-989, 2013.
    • (2013) American Journal of Gastroenterology , vol.108 , Issue.6 , pp. 981-989
    • Sears, D.M.1    Cohen, D.C.2    Ackerman, K.3    Ma, J.E.4    Song, J.5
  • 45
    • 84952780055 scopus 로고    scopus 로고
    • Acceptability and yield of birth-cohort screening for hepatitis C virus in a Canadian population being screened for colorectal cancer: A cross-sectional study
    • R. P. Myers, P. Crotty, S. Town et al., "Acceptability and yield of birth-cohort screening for hepatitis C virus in a Canadian population being screened for colorectal cancer: A cross-sectional study, " CMAJ Open, vol. 3, no. 1, pp. E62-E67, 2015.
    • (2015) CMAJ Open , vol.3 , Issue.1 , pp. E62-E67
    • Myers, R.P.1    Crotty, P.2    Town, S.3
  • 46
    • 84947553516 scopus 로고    scopus 로고
    • Epidemiology of hepatitis C virus: A battle on new frontiers
    • N. J. Shire and K. E. Sherman, "Epidemiology of hepatitis C virus: A battle on new frontiers, " Gastroenterology Clinics of North America, vol. 44, no. 4, pp. 699-716, 2015.
    • (2015) Gastroenterology Clinics of North America , vol.44 , Issue.4 , pp. 699-716
    • Shire, N.J.1    Sherman, K.E.2
  • 47
    • 44849129152 scopus 로고    scopus 로고
    • Costeffectiveness of the national screening program for hepatitis C virus in the general population and the high-risk groups
    • J. Nakamura, K. Terajima, Y. Aoyagi, and K. Akazawa, "Costeffectiveness of the national screening program for hepatitis C virus in the general population and the high-risk groups, " The Tohoku Journal of ExperimentalMedicine, vol. 215, no. 1, pp. 33-42, 2008.
    • (2008) The Tohoku Journal of ExperimentalMedicine , vol.215 , Issue.1 , pp. 33-42
    • Nakamura, J.1    Terajima, K.2    Aoyagi, Y.3    Akazawa, K.4
  • 48
    • 84876190039 scopus 로고    scopus 로고
    • Infection with hepatitis B and C virus in Europe: A systematic review of prevalence and costeffectiveness of screening
    • S. J. M. Hahné, I. K. Veldhuijzen, L. Wiessing, T.-A. Lim, M. Salminen, and M. V. D. Laar, "Infection with hepatitis B and C virus in Europe: A systematic review of prevalence and costeffectiveness of screening, " BMC Infectious Diseases, vol. 13, no. 1, article 181, 2013.
    • (2013) BMC Infectious Diseases , vol.13 , Issue.1
    • Hahné, S.J.M.1    Veldhuijzen, I.K.2    Wiessing, L.3    Lim, T.-A.4    Salminen, M.5    Laar, M.V.D.6
  • 49
    • 84929518027 scopus 로고    scopus 로고
    • Improved hepatitis C screening and treatment in people who inject drugs should be a priority in Europe
    • A. Kautz, L. Chavdarova, and M. Walker, "Improved hepatitis C screening and treatment in people who inject drugs should be a priority in Europe, " BMC InfectiousDiseases, vol. 14, supplement 6, article S3, 2014.
    • (2014) BMC InfectiousDiseases , vol.14
    • Kautz, A.1    Chavdarova, L.2    Walker, M.3
  • 50
  • 51
    • 84880174906 scopus 로고    scopus 로고
    • Formal hepatitis C education enhances HCV care coordination, expedites HCV treatment and improves antiviral response
    • S. Lubega, U. Agbim, M. Surjadi, M. Mahoney, and M. Khalili, "Formal hepatitis C education enhances HCV care coordination, expedites HCV treatment and improves antiviral response, " Liver International, vol. 33, no. 7, pp. 999-1007, 2013.
    • (2013) Liver International , vol.33 , Issue.7 , pp. 999-1007
    • Lubega, S.1    Agbim, U.2    Surjadi, M.3    Mahoney, M.4    Khalili, M.5
  • 52
    • 84865091292 scopus 로고    scopus 로고
    • Provider and patient correlates of provider decisions to recommend HCV treatment to HIV Co-infected patients
    • G. Wagner, K. C. Osilla, J. Garnett et al., "Provider and patient correlates of provider decisions to recommend HCV treatment to HIV Co-infected patients, " Journal of the International Association of Physicians in AIDS Care, vol. 11, no. 4, pp. 245-251, 2012.
    • (2012) Journal of the International Association of Physicians in AIDS Care , vol.11 , Issue.4 , pp. 245-251
    • Wagner, G.1    Osilla, K.C.2    Garnett, J.3
  • 53
    • 84898984691 scopus 로고    scopus 로고
    • Hepatitis and liver disease knowledge and preventive practices among health workers in Mexico: A cross-sectional study
    • N. Islam, Y. N. Flores, P. Ramirez, R. Bastani, and J. Salmerón, "Hepatitis and liver disease knowledge and preventive practices among health workers in Mexico: A cross-sectional study, " International Journal of PublicHealth, vol. 59, no. 2, pp. 381-394, 2014.
    • (2014) International Journal of PublicHealth , vol.59 , Issue.2 , pp. 381-394
    • Islam, N.1    Flores, Y.N.2    Ramirez, P.3    Bastani, R.4    Salmerón, J.5
  • 54
    • 79952675044 scopus 로고    scopus 로고
    • Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia
    • J. Grebely, J. Bryant, P. Hull et al., "Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia, " Journal of Viral Hepatitis, vol. 18, no. 4, pp. e104-e116, 2011.
    • (2011) Journal of Viral Hepatitis , vol.18 , Issue.4 , pp. e104-e116
    • Grebely, J.1    Bryant, J.2    Hull, P.3
  • 55
    • 84891352634 scopus 로고    scopus 로고
    • Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the infectious diseases society of America
    • J. A. Aberg, J. E. Gallant, K. G. Ghanem, P. Emmanuel, B. S. Zingman, and M. A. Horberg, "Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the infectious diseases society of America, " Clinical Infectious Diseases, vol. 58, no. 1, pp. 1-10, 2014.
    • (2014) Clinical Infectious Diseases , vol.58 , Issue.1 , pp. 1-10
    • Aberg, J.A.1    Gallant, J.E.2    Ghanem, K.G.3    Emmanuel, P.4    Zingman, B.S.5    Horberg, M.A.6
  • 56
    • 84864150288 scopus 로고    scopus 로고
    • Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men
    • B. P. Linas, A. Y. Wong, B. R. Schackman, A. Y. Kim, and K. A. Freedberg, "Cost-effective screening for acute hepatitis C virus infection in hiv-infected men who have sex with men, " Clinical Infectious Diseases, vol. 55, no. 2, pp. 279-290, 2012.
    • (2012) Clinical Infectious Diseases , vol.55 , Issue.2 , pp. 279-290
    • Linas, B.P.1    Wong, A.Y.2    Schackman, B.R.3    Kim, A.Y.4    Freedberg, K.A.5
  • 57
    • 84868032525 scopus 로고    scopus 로고
    • Hepatitis C virus infections in the swiss HIV cohort study: A rapidly evolving epidemic
    • G. Wandeler, T. Gsponer, A. Bregenzer et al., "Hepatitis C virus infections in the swiss HIV cohort study: A rapidly evolving epidemic, " Clinical Infectious Diseases, vol. 55, no. 10, pp. 1408-1416, 2012.
    • (2012) Clinical Infectious Diseases , vol.55 , Issue.10 , pp. 1408-1416
    • Wandeler, G.1    Gsponer, T.2    Bregenzer, A.3
  • 58
    • 84878879884 scopus 로고    scopus 로고
    • Incident hepatitis C virus infection in men who have sex with men: A prospective cohort analysis, 1984-2011
    • M. D. Witt, E. C. Seaberg, A. Darilay et al., "Incident hepatitis C virus infection in men who have sex with men: A prospective cohort analysis, 1984-2011, " Clinical Infectious Diseases, vol. 57, no. 1, pp. 77-84, 2013.
    • (2013) Clinical Infectious Diseases , vol.57 , Issue.1 , pp. 77-84
    • Witt, M.D.1    Seaberg, E.C.2    Darilay, A.3
  • 59
    • 84866175677 scopus 로고    scopus 로고
    • HCV seroconversion among never-injecting heroin users at baseline: No predictorsidentified other than starting injection
    • M. J. Bravo, F. Vallejo, G. Barrio et al., "HCV seroconversion among never-injecting heroin users at baseline: no predictorsidentified other than starting injection, " International Journal of Drug Policy, vol. 23, no. 5, pp. 415-419, 2012.
    • (2012) International Journal of Drug Policy , vol.23 , Issue.5 , pp. 415-419
    • Bravo, M.J.1    Vallejo, F.2    Barrio, G.3
  • 60
    • 79951522447 scopus 로고    scopus 로고
    • Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006
    • I. T. Williams, B. P. Bell, W. Kuhnert, andM. J. Alter, "Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006, " Archives of Internal Medicine, vol. 171, no. 3, pp. 242-248, 2011.
    • (2011) Archives of Internal Medicine , vol.171 , Issue.3 , pp. 242-248
    • Williams, I.T.1    Bell, B.P.2    Kuhnert, W.3    Alter, M.J.4
  • 61
    • 84941807523 scopus 로고    scopus 로고
    • Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum
    • J. P. Meyer, Y. Moghimi, R. Marcus, J. K. Lim, A. H. Litwin, and F. L. Altice, "Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum, " International Journal of Drug Policy, vol. 26, no. 10, pp. 922-935, 2015.
    • (2015) International Journal of Drug Policy , vol.26 , Issue.10 , pp. 922-935
    • Meyer, J.P.1    Moghimi, Y.2    Marcus, R.3    Lim, J.K.4    Litwin, A.H.5    Altice, F.L.6
  • 62
    • 84871245811 scopus 로고    scopus 로고
    • Baseline characteristics and mortality among people in care for chronic viral hepatitis: The chronic hepatitis cohort study
    • A. C. Moorman, S. C. Gordon, L. B. Rupp et al., "Baseline characteristics and mortality among people in care for chronic viral hepatitis: The chronic hepatitis cohort study, " Clinical Infectious Diseases, vol. 56, no. 1, pp. 40-50, 2013.
    • (2013) Clinical Infectious Diseases , vol.56 , Issue.1 , pp. 40-50
    • Moorman, A.C.1    Gordon, S.C.2    Rupp, L.B.3
  • 63
    • 84987623638 scopus 로고    scopus 로고
    • Evaluating a hepatitis c quality gap: Missed opportunities for HCV-related cares
    • Y. Liu, R. H. Lawrence, Y. Falck-Ytter, B. Watts, andA. A. Hirsch, "Evaluating a hepatitis c quality gap: missed opportunities for HCV-related cares, " American Journal ofManaged Care, vol. 20, no. 7, pp. e257-e264, 2014.
    • (2014) American Journal OfManaged Care , vol.20 , Issue.7 , pp. e257-e264
    • Liu, Y.1    Lawrence, R.H.2    Falck-Ytter, Y.3    Watts, B.4    Hirsch, A.A.5
  • 64
    • 34247200049 scopus 로고    scopus 로고
    • Reasons why patients infected with chronic hepatitisCvirus choose to defer treatment: Do they alter their decision with time?
    • O. S. Khokhar and J. H. Lewis, "Reasons why patients infected with chronic hepatitisCvirus choose to defer treatment: do they alter their decision with time?" Digestive Diseases and Sciences, vol. 52, no. 5, pp. 1168-1176, 2007.
    • (2007) Digestive Diseases and Sciences , vol.52 , Issue.5 , pp. 1168-1176
    • Khokhar, O.S.1    Lewis, J.H.2
  • 65
    • 79958195203 scopus 로고    scopus 로고
    • Outcomes of treatment for hepatitis C virus infection by primary care providers
    • S. Arora, K. Thornton, G. Murata et al., "Outcomes of treatment for hepatitis C virus infection by primary care providers, " New England Journal of Medicine, vol. 364, no. 23, pp. 2199-2207, 2011.
    • (2011) New England Journal of Medicine , vol.364 , Issue.23 , pp. 2199-2207
    • Arora, S.1    Thornton, K.2    Murata, G.3
  • 66
    • 84867714206 scopus 로고    scopus 로고
    • Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection
    • B. T. Clark, G. Garcia-Tsao, and L. Fraenkel, "Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection, " Patient Preference and Adherence, vol. 6, pp. 285-295, 2012.
    • (2012) Patient Preference and Adherence , vol.6 , pp. 285-295
    • Clark, B.T.1    Garcia-Tsao, G.2    Fraenkel, L.3
  • 67
    • 84949561087 scopus 로고    scopus 로고
    • Update on hepatitis C: Direct-acting antivirals
    • L. L. Seifert, R. B. Perumpail, and A. Ahmed, "Update on hepatitis C: direct-acting antivirals, " World Journal of Hepatology, vol. 7, no. 28, pp. 2829-2833, 2015.
    • (2015) World Journal of Hepatology , vol.7 , Issue.28 , pp. 2829-2833
    • Seifert, L.L.1    Perumpail, R.B.2    Ahmed, A.3
  • 70
    • 67651083226 scopus 로고    scopus 로고
    • Hepatitis C treatment for injection drug users: A review of the available evidence
    • M. Hellard, R. Sacks?Davis, and J. Gold, "Hepatitis C treatment for injection drug users: A review of the available evidence, " Clinical Infectious Diseases, vol. 49, no. 4, pp. 561-573, 2009.
    • (2009) Clinical Infectious Diseases , vol.49 , Issue.4 , pp. 561-573
    • Hellard, M.1    Sacksdavis, R.2    Gold, J.3
  • 71
    • 23744484452 scopus 로고    scopus 로고
    • Barriers to the treatment of hepatitis C: Patient, provider, and system factors
    • J. A. Morrill, M. Shrestha, and R. W. Grant, "Barriers to the treatment of hepatitis C: patient, provider, and system factors, " Journal of General InternalMedicine, vol. 20, no. 8, pp. 754-758, 2005.
    • (2005) Journal of General InternalMedicine , vol.20 , Issue.8 , pp. 754-758
    • Morrill, J.A.1    Shrestha, M.2    Grant, R.W.3
  • 72
    • 84901658602 scopus 로고    scopus 로고
    • Lack of access to treatment as a barrier to HCV screening: A facility-based assessment in the Indian health service
    • B. Reilley, J. Leston, J. T. Redd, and R. Geiger, "Lack of access to treatment as a barrier to HCV screening: A facility-based assessment in the Indian health service, " Journal of PublicHealth Management and Practice, vol. 20, no. 4, pp. 420-423, 2014.
    • (2014) Journal of PublicHealth Management and Practice , vol.20 , Issue.4 , pp. 420-423
    • Reilley, B.1    Leston, J.2    Redd, J.T.3    Geiger, R.4
  • 73
    • 84876153751 scopus 로고    scopus 로고
    • A global view of hepatitis C: Physician knowledge, opinions, and perceived barriers to care
    • C. E. McGowan, A. Monis, B. R. Bacon et al., "A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care, " Hepatology, vol. 57, no. 4, pp. 1325-1332, 2013.
    • (2013) Hepatology , vol.57 , Issue.4 , pp. 1325-1332
    • McGowan, C.E.1    Monis, A.2    Bacon, B.R.3
  • 74
    • 84868151001 scopus 로고    scopus 로고
    • Linkage into specialist hepatitis C treatment services of injecting drug users attending a needle syringe program-based primary healthcare centre
    • M. M. Islam, L. Topp, K. M. Conigrave et al., "Linkage into specialist hepatitis C treatment services of injecting drug users attending a needle syringe program-based primary healthcare centre, " Journal of Substance Abuse Treatment, vol. 43, no. 4, pp. 440-445, 2012.
    • (2012) Journal of Substance Abuse Treatment , vol.43 , Issue.4 , pp. 440-445
    • Islam, M.M.1    Topp, L.2    Conigrave, K.M.3
  • 75
    • 84868147307 scopus 로고    scopus 로고
    • Concurrent group treatment for hepatitis C: Implementation and outcomes in a methadone maintenance treatment program
    • M. R. Stein, I. J. Soloway, K. S. Jefferson, R. J. Roose, J. H. Arnsten, and A. H. Litwin, "Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program, " Journal of Substance Abuse Treatment, vol. 43, no. 4, pp. 424-432, 2012.
    • (2012) Journal of Substance Abuse Treatment , vol.43 , Issue.4 , pp. 424-432
    • Stein, M.R.1    Soloway, I.J.2    Jefferson, K.S.3    Roose, R.J.4    Arnsten, J.H.5    Litwin, A.H.6
  • 76
    • 84881004592 scopus 로고    scopus 로고
    • Models of care for the management of hepatitis C virus among people who inject drugs: One size does not fit all
    • P. Bruggmann and A. H. Litwin, "Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all, " Clinical Infectious Diseases, vol. 57, supplement 2, pp. S56-S61, 2013.
    • (2013) Clinical Infectious Diseases , vol.57 , pp. S56-S61
    • Bruggmann, P.1    Litwin, A.H.2
  • 77
    • 84944279905 scopus 로고    scopus 로고
    • Integrated care increases treatment and improves outcomes of patients with chronic hepatitis C virus infection and psychiatric illness or substance abuse
    • S. B. Ho, N. Bräu, R. Cheung et al., "Integrated care increases treatment and improves outcomes of patients with chronic hepatitis C virus infection and psychiatric illness or substance abuse, " Clinical Gastroenterology and Hepatology, vol. 13, no. 11, pp. 2005-2014, 2015.
    • (2015) Clinical Gastroenterology and Hepatology , vol.13 , Issue.11 , pp. 2005-2014
    • Ho, S.B.1    Bräu, N.2    Cheung, R.3
  • 78
    • 84890122831 scopus 로고    scopus 로고
    • Clinical outcomes of hepatitis C treated with pegylated interferon and ribavirin via telemedicine consultation inNorthern California
    • L. Rossaro, C. Torruellas, S. Dhaliwal et al., "Clinical outcomes of hepatitis C treated with pegylated interferon and ribavirin via telemedicine consultation inNorthern California, " Digestive Diseases and Sciences, vol. 58, no. 12, pp. 3620-3625, 2013.
    • (2013) Digestive Diseases and Sciences , vol.58 , Issue.12 , pp. 3620-3625
    • Rossaro, L.1    Torruellas, C.2    Dhaliwal, S.3
  • 79
    • 84865422792 scopus 로고    scopus 로고
    • Improving access to hepatitis C care for urban, underserved patients using a primary care-based hepatitis C clinic
    • L. Miller, S.-A. Fluker, M. Osborn, X. Liu, and A. Strawder, "Improving access to hepatitis C care for urban, underserved patients using a primary care-based hepatitis C clinic, " Journal of the National Medical Association, vol. 104, no. 5-6, pp. 244-250, 2012.
    • (2012) Journal of the National Medical Association , vol.104 , Issue.5-6 , pp. 244-250
    • Miller, L.1    Fluker, S.-A.2    Osborn, M.3    Liu, X.4    Strawder, A.5
  • 80
    • 84931560419 scopus 로고    scopus 로고
    • Results from a geographically focused, community-based HCV screening, linkage-to-care and patient navigation program
    • S. B. Trooskin, J. Poceta, C. M. Towey et al., "Results from a geographically focused, community-based HCV screening, linkage-to-care and patient navigation program, " Journal of General Internal Medicine, vol. 30, no. 7, pp. 950-957, 2015.
    • (2015) Journal of General Internal Medicine , vol.30 , Issue.7 , pp. 950-957
    • Trooskin, S.B.1    Poceta, J.2    Towey, C.M.3
  • 81
    • 84931082688 scopus 로고    scopus 로고
    • Identification and linkage to care of HCV-infected persons in five health centers-Philadelphia, Pennsylvania, 2012-2014
    • C. Coyle, K. Viner, E. Hughes et al., "Identification and linkage to care of HCV-infected persons in five health centers-Philadelphia, Pennsylvania, 2012-2014, " Morbidity and MortalityWeekly Report, vol. 64, no. 17, pp. 459-463, 2015.
    • (2015) Morbidity and MortalityWeekly Report , vol.64 , Issue.17 , pp. 459-463
    • Coyle, C.1    Viner, K.2    Hughes, E.3
  • 82
    • 84956871250 scopus 로고    scopus 로고
    • Advances in hepatitis C therapy: What is the current state-what come's next?
    • S. Zopf, A. E. Kremer, M. F. Neurath, and J. Siebler, "Advances in hepatitis C therapy: what is the current state-what come's next?" World Journal of Hepatology, vol. 8, no. 3, pp. 139-147, 2016.
    • (2016) World Journal of Hepatology , vol.8 , Issue.3 , pp. 139-147
    • Zopf, S.1    Kremer, A.E.2    Neurath, M.F.3    Siebler, J.4
  • 83
    • 84990028964 scopus 로고    scopus 로고
    • Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens
    • J. M. Pawlotsky, "Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens, " Gastroenterology, vol. 151, no. 1, pp. 70-86, 2016.
    • (2016) Gastroenterology , vol.151 , Issue.1 , pp. 70-86
    • Pawlotsky, J.M.1
  • 86
    • 84943328674 scopus 로고    scopus 로고
    • Consideration of viral resistance for optimization of direct antiviral therapy of hepatitis C virus genotype 1-infected patients
    • J. Dietz, S. Susser, C. Berkowski, D. Perner, S. Zeuzem, and C. Sarrazin, "Consideration of viral resistance for optimization of direct antiviral therapy of hepatitis C virus genotype 1-infected patients, " PLoS ONE, vol. 10, no. 8, article e0134395, 2015.
    • (2015) PLoS ONE , vol.10 , Issue.8
    • Dietz, J.1    Susser, S.2    Berkowski, C.3    Perner, D.4    Zeuzem, S.5    Sarrazin, C.6
  • 87
    • 84873041135 scopus 로고    scopus 로고
    • Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment
    • D. J. Bartels, J. C. Sullivan, E. Z. Zhang et al., "Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment, " Journal ofVirology, vol. 87, no. 3, pp. 1544-1553, 2013.
    • (2013) Journal OfVirology , vol.87 , Issue.3 , pp. 1544-1553
    • Bartels, D.J.1    Sullivan, J.C.2    Zhang, E.Z.3
  • 88
    • 84896520682 scopus 로고    scopus 로고
    • Antiviral therapy of hepatitis C in 2014: Do we need resistance testing?
    • M. D. Schneider and C. Sarrazin, "Antiviral therapy of hepatitis C in 2014: do we need resistance testing?" Antiviral Research, vol. 105, no. 1, pp. 64-71, 2014.
    • (2014) Antiviral Research , vol.105 , Issue.1 , pp. 64-71
    • Schneider, M.D.1    Sarrazin, C.2
  • 89
    • 84927798764 scopus 로고    scopus 로고
    • Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies
    • O. Lenz, T. Verbinnen, B. Fevery et al., "Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies, " Journal of Hepatology, vol. 62, no. 5, pp. 1008-1014, 2015.
    • (2015) Journal of Hepatology , vol.62 , Issue.5 , pp. 1008-1014
    • Lenz, O.1    Verbinnen, T.2    Fevery, B.3
  • 90
    • 84936804505 scopus 로고    scopus 로고
    • Successes and challenges on the road to cure hepatitisC
    • S. M. Horner, S. Naggie, and R. C. Condit, "Successes and challenges on the road to cure hepatitisC, " PLoS Pathogens, vol. 11, no. 6, article e1004854, 2015.
    • (2015) PLoS Pathogens , vol.11 , Issue.6
    • Horner, S.M.1    Naggie, S.2    Condit, R.C.3
  • 91
    • 84958161018 scopus 로고    scopus 로고
    • Evaluation of a commercial real-time PCR kit for the detection of the Q80K polymorphism in plasma from HCV genotype 1a infected patients
    • I. Vicenti, F. Falasca, L. Sticchi, B. Bruzzone, O. Turriziani, and M. Zazzi, "Evaluation of a commercial real-time PCR kit for the detection of the Q80K polymorphism in plasma from HCV genotype 1a infected patients, " Journal of Clinical Virology, vol. 76, pp. 20-23, 2016.
    • (2016) Journal of Clinical Virology , vol.76 , pp. 20-23
    • Vicenti, I.1    Falasca, F.2    Sticchi, L.3    Bruzzone, B.4    Turriziani, O.5    Zazzi, M.6
  • 92
    • 84906053496 scopus 로고    scopus 로고
    • Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): A phase 3, randomised, double-blind, placebocontrolled trial
    • I. M. Jacobson, G. J. Dore, G. R. Foster et al., "Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): A phase 3, randomised, double-blind, placebocontrolled trial, " The Lancet, vol. 384, no. 9941, pp. 403-413, 2014.
    • (2014) The Lancet , vol.384 , Issue.9941 , pp. 403-413
    • Jacobson, I.M.1    Dore, G.J.2    Foster, G.R.3
  • 93
    • 84906059095 scopus 로고    scopus 로고
    • Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatmentnaive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): A randomised, double-blind, placebocontrolled phase 3 trial
    • M. Manns, P. Marcellin, F. Poordad et al., "Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatmentnaive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): A randomised, double-blind, placebocontrolled phase 3 trial, " The Lancet, vol. 384, no. 9941, pp. 414-426, 2014.
    • (2014) The Lancet , vol.384 , Issue.9941 , pp. 414-426
    • Manns, M.1    Marcellin, P.2    Poordad, F.3
  • 94
    • 84901217985 scopus 로고    scopus 로고
    • Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: A phase 3 trial
    • X. Forns, E. Lawitz, S. Zeuzem et al., "Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: A phase 3 trial, " Gastroenterology, vol. 146, no. 7, pp. 1669. e3-1679. e3, 2014.
    • (2014) Gastroenterology , vol.146 , Issue.7 , pp. 1669e3-1679e3
    • Forns, X.1    Lawitz, E.2    Zeuzem, S.3
  • 95
    • 84925619517 scopus 로고    scopus 로고
    • Efficacy and safety of simeprevir with PegIFN/ribavirin in nä?ve or experienced patients infected with chronic HCV genotype 4
    • C. Moreno, C. Hezode, P. Marcellin et al., "Efficacy and safety of simeprevir with PegIFN/ribavirin in nä?ve or experienced patients infected with chronic HCV genotype 4, " Journal of Hepatology, vol. 62, no. 5, pp. 1047-1055, 2015.
    • (2015) Journal of Hepatology , vol.62 , Issue.5 , pp. 1047-1055
    • Moreno, C.1    Hezode, C.2    Marcellin, P.3
  • 96
    • 84922318694 scopus 로고    scopus 로고
    • Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region
    • C. Sarrazin, E. Lathouwers, M. Peeters et al., "Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region, " Antiviral Research, vol. 116, pp. 10-16, 2015.
    • (2015) Antiviral Research , vol.116 , pp. 10-16
    • Sarrazin, C.1    Lathouwers, E.2    Peeters, M.3
  • 97
    • 84936936737 scopus 로고    scopus 로고
    • Worldwide distribution of the NS3 gene 80K polymorphism among circulating hepatitis C genotype 1 viruses: Implication for simeprevir usage
    • L. L. Vidãl, A. F. Santos, and M. A. Soares, "Worldwide distribution of the NS3 gene 80K polymorphism among circulating hepatitis C genotype 1 viruses: implication for simeprevir usage, " Journal of Antimicrobial Chemotherapy, vol. 70, no. 7, Article ID dkv081, pp. 2024-2027, 2014.
    • (2014) Journal of Antimicrobial Chemotherapy , vol.70 , Issue.7 , pp. 2024-2027
    • Vidãl, L.L.1    Santos, A.F.2    Soares, M.A.3
  • 98
    • 84940498353 scopus 로고    scopus 로고
    • Diversity of 1, 213 hepatitis C virus NS3 protease sequences froma clinical virology laboratory database inMarseille university hospitals, southeastern France
    • H. Hajji, S. Aherfi, A. Motte et al., "Diversity of 1, 213 hepatitis C virus NS3 protease sequences froma clinical virology laboratory database inMarseille university hospitals, southeastern France, " Journal of Medical Virology, vol. 87, no. 11, pp. 1921-1933, 2015.
    • (2015) Journal of Medical Virology , vol.87 , Issue.11 , pp. 1921-1933
    • Hajji, H.1    Aherfi, S.2    Motte, A.3
  • 99
    • 84979066379 scopus 로고    scopus 로고
    • Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2)
    • E. Lawitz, G. Matusow, E. DeJesus et al., "Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2), " Hepatology, vol. 64, no. 2, pp. 360-369, 2016.
    • (2016) Hepatology , vol.64 , Issue.2 , pp. 360-369
    • Lawitz, E.1    Matusow, G.2    DeJesus, E.3
  • 100
    • 84954399628 scopus 로고    scopus 로고
    • The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
    • C. Sarrazin, "The importance of resistance to direct antiviral drugs in HCV infection in clinical practice, " Journal of Hepatology, vol. 64, no. 2, pp. 486-504, 2016.
    • (2016) Journal of Hepatology , vol.64 , Issue.2 , pp. 486-504
    • Sarrazin, C.1
  • 101
    • 77956116880 scopus 로고    scopus 로고
    • Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system
    • R. A. Fridell, D. Qiu, C. Wang, L. Valera, andM. Gao, "Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system, " Antimicrobial Agents and Chemotherapy, vol. 54, no. 9, pp. 3641-3650, 2010.
    • (2010) Antimicrobial Agents and Chemotherapy , vol.54 , Issue.9 , pp. 3641-3650
    • Fridell, R.A.1    Qiu, D.2    Wang, C.3    Valera, L.4    Gao, M.5
  • 102
    • 84879693219 scopus 로고    scopus 로고
    • Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options
    • Y. Suzuki, K. Ikeda, F. Suzuki et al., "Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options, " Journal of Hepatology, vol. 58, no. 4, pp. 655-662, 2013.
    • (2013) Journal of Hepatology , vol.58 , Issue.4 , pp. 655-662
    • Suzuki, Y.1    Ikeda, K.2    Suzuki, F.3
  • 103
    • 84863860109 scopus 로고    scopus 로고
    • Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b
    • F. Suzuki, H. Sezaki, N. Akuta et al., "Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b, " Journal of Clinical Virology, vol. 54, no. 4, pp. 352-354, 2012.
    • (2012) Journal of Clinical Virology , vol.54 , Issue.4 , pp. 352-354
    • Suzuki, F.1    Sezaki, H.2    Akuta, N.3
  • 104
    • 84979911433 scopus 로고    scopus 로고
    • Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals
    • N. Coppola, C. Minichini, M. Starace, C. Sagnelli, and E. Sagnelli, "Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals, " Journal ofMedical Virology, vol. 88, no. 10, pp. 1659-1671, 2016.
    • (2016) Journal OfMedical Virology , vol.88 , Issue.10 , pp. 1659-1671
    • Coppola, N.1    Minichini, C.2    Starace, M.3    Sagnelli, C.4    Sagnelli, E.5
  • 105
    • 84964762303 scopus 로고    scopus 로고
    • Long-term followup of treatment-emergent resistance-associated variants in NS3, NS5A and NS5 B with paritaprevir/r-, ombitasvir-and dasabuvir-based regimens
    • P. Krishnan, R. Tripathi, G. Schnell et al., "Long-term followup of treatment-emergent resistance-associated variants in NS3, NS5A and NS5 B with paritaprevir/r-, ombitasvir-and dasabuvir-based regimens, " Journal of Hepatology, vol. 62, supplement 2, p. S220, 2015.
    • (2015) Journal of Hepatology , vol.62 , pp. S220
    • Krishnan, P.1    Tripathi, R.2    Schnell, G.3
  • 106
    • 84883219967 scopus 로고    scopus 로고
    • Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir
    • F. Mcphee, D. Hernandez, F. Yu et al., "Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir, " Hepatology, vol. 58, no. 3, pp. 902-911, 2013.
    • (2013) Hepatology , vol.58 , Issue.3 , pp. 902-911
    • Mcphee, F.1    Hernandez, D.2    Yu, F.3
  • 107
    • 84964762607 scopus 로고    scopus 로고
    • Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir
    • H. Dvory-Sobol, D. Wyles, W. Ouyang et al., "Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir, " Journal of Hepatology, vol. 62, supplement 2, p. S221, 2015.
    • (2015) Journal of Hepatology , vol.62 , pp. S221
    • Dvory-Sobol, H.1    Wyles, D.2    Ouyang, W.3
  • 108
    • 84942864509 scopus 로고    scopus 로고
    • Resistance to directacting antiviral agents: Clinical utility and significance
    • V. Cento, S. Chevaliez, and C. F. Perno, "Resistance to directacting antiviral agents: clinical utility and significance, " Current Opinion in HIV and AIDS, vol. 10, no. 5, pp. 381-389, 2015.
    • (2015) Current Opinion in HIV and AIDS , vol.10 , Issue.5 , pp. 381-389
    • Cento, V.1    Chevaliez, S.2    Perno, C.F.3
  • 109
    • 84946945495 scopus 로고    scopus 로고
    • Management of direct-acting antiviral agent failures
    • M. Buti, M. Riveiro-Barciela, and R. Esteban, "Management of direct-acting antiviral agent failures, " Journal of Hepatology, vol. 63, no. 6, pp. 1511-1522, 2015.
    • (2015) Journal of Hepatology , vol.63 , Issue.6 , pp. 1511-1522
    • Buti, M.1    Riveiro-Barciela, M.2    Esteban, R.3
  • 110
    • 40849097775 scopus 로고    scopus 로고
    • Rates of evolutionary change in viruses: Patterns and determinants
    • S. Duffy, L. A. Shackelton, and E. C. Holmes, "Rates of evolutionary change in viruses: patterns and determinants, " Nature Reviews Genetics, vol. 9, no. 4, pp. 267-276, 2008.
    • (2008) Nature Reviews Genetics , vol.9 , Issue.4 , pp. 267-276
    • Duffy, S.1    Shackelton, L.A.2    Holmes, E.C.3
  • 111
    • 0028945033 scopus 로고
    • Genetic heterogeneity of hepatitis C virus: Quasispecies and genotypes
    • J. Bukh, R. H. Miller, and R. H. Purcell, "Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes, " Seminars in Liver Disease, vol. 15, no. 1, pp. 41-63, 1995.
    • (1995) Seminars in Liver Disease , vol.15 , Issue.1 , pp. 41-63
    • Bukh, J.1    Miller, R.H.2    Purcell, R.H.3
  • 112
    • 0033429088 scopus 로고    scopus 로고
    • Viral heterogeneity of the hepatitis C virus
    • P. Simmonds, "Viral heterogeneity of the hepatitis C virus, " Journal of Hepatology, vol. 31, supplement 1, pp. 54-60, 1999.
    • (1999) Journal of Hepatology , vol.31 , pp. 54-60
    • Simmonds, P.1
  • 113
    • 22344448015 scopus 로고    scopus 로고
    • Mutational escape fromCD8+ T cell immunity: HCV evolution, from chimpanzees to man
    • D. G. Bowen and C. M. Walker, "Mutational escape fromCD8+ T cell immunity: HCV evolution, from chimpanzees to man, " Journal of ExperimentalMedicine, vol. 201, no. 11, pp. 1709-1714, 2005.
    • (2005) Journal of ExperimentalMedicine , vol.201 , Issue.11 , pp. 1709-1714
    • Bowen, D.G.1    Walker, C.M.2
  • 114
    • 33847015308 scopus 로고    scopus 로고
    • HepatitisCvirus continuously escapes fromneutralizing antibody and T-cell responses during chronic infection in vivo
    • T. vonHahn, J. C. Yoon, H. Alter et al., "HepatitisCvirus continuously escapes fromneutralizing antibody and T-cell responses during chronic infection in vivo, " Gastroenterology, vol. 132, no. 2, pp. 667-678, 2007.
    • (2007) Gastroenterology , vol.132 , Issue.2 , pp. 667-678
    • VonHahn, T.1    Yoon, J.C.2    Alter, H.3
  • 115
    • 34249885360 scopus 로고    scopus 로고
    • Chronic infections with hepatotropic viruses: Mechanisms of impairment of cellular immune responses
    • B. Rehermann, "Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses, " Seminars in Liver Disease, vol. 27, no. 2, pp. 152-160, 2007.
    • (2007) Seminars in Liver Disease , vol.27 , Issue.2 , pp. 152-160
    • Rehermann, B.1
  • 116
    • 33947421722 scopus 로고    scopus 로고
    • Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection
    • A. Penna, M. Pilli, A. Zerbini et al., "Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection, " Hepatology, vol. 45, no. 3, pp. 588-601, 2007.
    • (2007) Hepatology , vol.45 , Issue.3 , pp. 588-601
    • Penna, A.1    Pilli, M.2    Zerbini, A.3
  • 117
    • 85027929950 scopus 로고    scopus 로고
    • Persistent hepatitis C virus (HCV) infection impairs HCV-specific cytotoxic T cell reactivity through Mcl-1/Bim imbalance due to CD127 down-regulation
    • J. R. Larrubia, M. U. Lokhande, S. Garca-Garzõn et al., "Persistent hepatitis C virus (HCV) infection impairs HCV-specific cytotoxic T cell reactivity through Mcl-1/Bim imbalance due to CD127 down-regulation, " Journal of Viral Hepatitis, vol. 20, no. 2, pp. 85-94, 2013.
    • (2013) Journal of Viral Hepatitis , vol.20 , Issue.2 , pp. 85-94
    • Larrubia, J.R.1    Lokhande, M.U.2    Garca-Garzõn, S.3
  • 118
    • 38649100951 scopus 로고    scopus 로고
    • Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies
    • J. M. Timpe, Z. Stamataki, A. Jennings et al., "Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies, " Hepatology, vol. 47, no. 1, pp. 17-24, 2008.
    • (2008) Hepatology , vol.47 , Issue.1 , pp. 17-24
    • Timpe, J.M.1    Stamataki, Z.2    Jennings, A.3
  • 119
    • 84947425793 scopus 로고    scopus 로고
    • Progress in the development of vaccines for hepatitis C virus infection
    • F. Ghasemi, S. Rostami, and Z. Meshkat, "Progress in the development of vaccines for hepatitis C virus infection, " World Journal of Gastroenterology, vol. 21, no. 42, pp. 11984-12002, 2015.
    • (2015) World Journal of Gastroenterology , vol.21 , Issue.42 , pp. 11984-12002
    • Ghasemi, F.1    Rostami, S.2    Meshkat, Z.3
  • 120
    • 84885335829 scopus 로고    scopus 로고
    • Hepatitis C virus infection and related liver disease: The quest for the best animal model
    • L. Mailly, E. Robinet, P. Meuleman, T. F. Baumert, and M. B. Zeisel, "Hepatitis C virus infection and related liver disease: The quest for the best animal model, " Frontiers in Microbiology, vol. 4, article 213, 2013.
    • (2013) Frontiers in Microbiology , vol.4
    • Mailly, L.1    Robinet, E.2    Meuleman, P.3    Baumert, T.F.4    Zeisel, M.B.5
  • 121
    • 84860287115 scopus 로고    scopus 로고
    • Animal models for the study of hepatitis C virus infection and related liver disease
    • J. Bukh, "Animal models for the study of hepatitis C virus infection and related liver disease, " Gastroenterology, vol. 142, no. 6, pp. 1279. e3-1287. e3, 2012.
    • (2012) Gastroenterology , vol.142 , Issue.6 , pp. 1279e3-1287e3
    • Bukh, J.1
  • 122
    • 84905870295 scopus 로고    scopus 로고
    • Hepatitis C virus in the new era: Perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy
    • F. Ansaldi, A. Orsi, L. Sticchi, B. Bruzzone, and G. Icardi, "Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy, " World Journal of Gastroenterology, vol. 20, no. 29, pp. 9633-9652, 2014.
    • (2014) World Journal of Gastroenterology , vol.20 , Issue.29 , pp. 9633-9652
    • Ansaldi, F.1    Orsi, A.2    Sticchi, L.3    Bruzzone, B.4    Icardi, G.5
  • 123
    • 3843137346 scopus 로고    scopus 로고
    • A candidate vaccine based on the hepatitis C E1 protein: Tolerability and immunogenicity in healthy volunteers
    • G. Leroux-Roels, E. Depla, F. Hulstaert et al., "A candidate vaccine based on the hepatitis C E1 protein: Tolerability and immunogenicity in healthy volunteers, " Vaccine, vol. 22, no. 23-24, pp. 3080-3086, 2004.
    • (2004) Vaccine , vol.22 , Issue.23-24 , pp. 3080-3086
    • Leroux-Roels, G.1    Depla, E.2    Hulstaert, F.3
  • 124
    • 77955661037 scopus 로고    scopus 로고
    • Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults
    • S. E. Frey, M. Houghton, S. Coates et al., "Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults, " Vaccine, vol. 28, no. 38, pp. 6367-6373, 2010.
    • (2010) Vaccine , vol.28 , Issue.38 , pp. 6367-6373
    • Frey, S.E.1    Houghton, M.2    Coates, S.3
  • 125
    • 67549123833 scopus 로고    scopus 로고
    • Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX- vaccine: A phase i study in healthy volunteers
    • D. Drane, E. Maraskovsky, R. Gibson et al., "Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX- vaccine: A phase I study in healthy volunteers, " Human Vaccines, vol. 5, no. 3, pp. 151-157, 2009.
    • (2009) Human Vaccines , vol.5 , Issue.3 , pp. 151-157
    • Drane, D.1    Maraskovsky, E.2    Gibson, R.3
  • 126
    • 33646144429 scopus 로고    scopus 로고
    • Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: A randomized, placebo controlled trial for dose optimization in 128 healthy subjects
    • C. Firbas, B. Jilma, E. Tauber et al., "Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: A randomized, placebo controlled trial for dose optimization in 128 healthy subjects, " Vaccine, vol. 24, no. 20, pp. 4343-4353, 2006.
    • (2006) Vaccine , vol.24 , Issue.20 , pp. 4343-4353
    • Firbas, C.1    Jilma, B.2    Tauber, E.3
  • 127
    • 77549085401 scopus 로고    scopus 로고
    • Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine
    • C. Firbas, T. Boehm, V. Buerger et al., "Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine, " Vaccine, vol. 28, no. 12, pp. 2397-2407, 2010.
    • (2010) Vaccine , vol.28 , Issue.12 , pp. 2397-2407
    • Firbas, C.1    Boehm, T.2    Buerger, V.3
  • 128
    • 84855388574 scopus 로고    scopus 로고
    • Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man
    • E. Barnes, A. Folgori, S. Capone et al., "Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man, " Science Translational Medicine, vol. 4, no. 115, Article ID 115ra1, 2012.
    • (2012) Science Translational Medicine , vol.4 , Issue.115
    • Barnes, E.1    Folgori, A.2    Capone, S.3
  • 129
    • 84954436919 scopus 로고    scopus 로고
    • Status of hepatitis C virus vaccination: Recent update
    • K. S. Abdelwahab and Z. N. A. Said, "Status of hepatitis C virus vaccination: recent update, " World Journal of Gastroenterology, vol. 22, no. 2, pp. 862-873, 2016.
    • (2016) World Journal of Gastroenterology , vol.22 , Issue.2 , pp. 862-873
    • Abdelwahab, K.S.1    Said, Z.N.A.2
  • 130
    • 42949111104 scopus 로고    scopus 로고
    • Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41
    • C. S. Klade, H. Wedemeyer, T. Berg et al., "Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41, " Gastroenterology, vol. 134, no. 5, pp. 1385. e1-1395. e1, 2008.
    • (2008) Gastroenterology , vol.134 , Issue.5 , pp. 1385e1-1395e1
    • Klade, C.S.1    Wedemeyer, H.2    Berg, T.3
  • 131
    • 67650734950 scopus 로고    scopus 로고
    • Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C
    • H. Wedemeyer, E. Schuller, V. Schlaphoff et al., "Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C, " Vaccine, vol. 27, no. 37, pp. 5142-5151, 2009.
    • (2009) Vaccine , vol.27 , Issue.37 , pp. 5142-5151
    • Wedemeyer, H.1    Schuller, E.2    Schlaphoff, V.3
  • 132
    • 34748815771 scopus 로고    scopus 로고
    • Phase i clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferonbased therapy
    • S. Yutani, A. Yamada, K. Yoshida et al., "Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferonbased therapy, " Vaccine, vol. 25, no. 42, pp. 7429-7435, 2007.
    • (2007) Vaccine , vol.25 , Issue.42 , pp. 7429-7435
    • Yutani, S.1    Yamada, A.2    Yoshida, K.3
  • 133
    • 80051490030 scopus 로고    scopus 로고
    • A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C
    • F. Habersetzer, G. Honnet, C. Bain et al., "A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C, " Gastroenterology, vol. 141, no. 3, pp. 890. e4-899. e4, 2011.
    • (2011) Gastroenterology , vol.141 , Issue.3 , pp. 890e4-899e4
    • Habersetzer, F.1    Honnet, G.2    Bain, C.3
  • 134
    • 84869202423 scopus 로고    scopus 로고
    • New therapeutic options for HCV infection in the monoclonal antibody era
    • G. A. Sautto, R. A. Diotti, and M. Clementi, "New therapeutic options for HCV infection in the monoclonal antibody era, " New Microbiologica, vol. 35, no. 4, pp. 387-397, 2012.
    • (2012) New Microbiologica , vol.35 , Issue.4 , pp. 387-397
    • Sautto, G.A.1    Diotti, R.A.2    Clementi, M.3
  • 135
    • 84871804469 scopus 로고    scopus 로고
    • Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases
    • M. Flego, A. Ascione, M. Cianfriglia, and S. Vella, "Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases, " BMC Medicine, vol. 11, article 4, 2013.
    • (2013) BMC Medicine , vol.11
    • Flego, M.1    Ascione, A.2    Cianfriglia, M.3    Vella, S.4
  • 136
    • 34247893277 scopus 로고    scopus 로고
    • Clinical evaluation (Phase I) of a human monoclonal antibody against hepatitis C virus: Safety and antiviral activity
    • E. Galun, N. A. Terrault, R. Eren et al., "Clinical evaluation (Phase I) of a human monoclonal antibody against hepatitis C virus: safety and antiviral activity, " Journal of Hepatology, vol. 46, no. 1, pp. 37-44, 2007.
    • (2007) Journal of Hepatology , vol.46 , Issue.1 , pp. 37-44
    • Galun, E.1    Terrault, N.A.2    Eren, R.3
  • 137
    • 33748778214 scopus 로고    scopus 로고
    • Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: Results of a phase 2 randomized study
    • T. D. Schiano, M. Charlton, Z. Younossi et al., "Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study, " Liver Transplantation, vol. 12, no. 9, pp. 1381-1389, 2006.
    • (2006) Liver Transplantation , vol.12 , Issue.9 , pp. 1381-1389
    • Schiano, T.D.1    Charlton, M.2    Younossi, Z.3
  • 138
    • 84875695802 scopus 로고    scopus 로고
    • Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: A randomized controlled study
    • R. T. Chung, F. D. Gordon, M. P. Curry et al., "Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: A randomized controlled study, " American Journal of Transplantation, vol. 13, no. 4, pp. 1047-1054, 2013.
    • (2013) American Journal of Transplantation , vol.13 , Issue.4 , pp. 1047-1054
    • Chung, R.T.1    Gordon, F.D.2    Curry, M.P.3
  • 139
    • 84878089612 scopus 로고    scopus 로고
    • ARandomized, doubleblind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection
    • D. Gardiner, J. Lalezari, E. Lawitz et al., "ARandomized, doubleblind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection, " PLoS ONE, vol. 8, no. 5, Article IDe63818, 2013.
    • (2013) PLoS ONE , vol.8 , Issue.5
    • Gardiner, D.1    Lalezari, J.2    Lawitz, E.3
  • 140
    • 84879141840 scopus 로고    scopus 로고
    • A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
    • B. Sangro, C. Gomez-Martin, M. De La Mata et al., "A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C, " Journal of Hepatology, vol. 59, no. 1, pp. 81-88, 2013.
    • (2013) Journal of Hepatology , vol.59 , Issue.1 , pp. 81-88
    • Sangro, B.1    Gomez-Martin, C.2    De La Mata, M.3
  • 141
    • 84934765248 scopus 로고    scopus 로고
    • Oral anti-CD3 immunotherapy for HCV-nonresponders is safe, promotes regulatory T cells and decreases viral load and liver enzyme levels: Results of a phase-2a placebo-controlled trial
    • W. Halota, P. Ferenci, D. Kozielewicz et al., "Oral anti-CD3 immunotherapy for HCV-nonresponders is safe, promotes regulatory T cells and decreases viral load and liver enzyme levels: results of a phase-2a placebo-controlled trial, " Journal of Viral Hepatitis, vol. 22, no. 8, pp. 651-657, 2015.
    • (2015) Journal of Viral Hepatitis , vol.22 , Issue.8 , pp. 651-657
    • Halota, W.1    Ferenci, P.2    Kozielewicz, D.3
  • 142
    • 58149388300 scopus 로고    scopus 로고
    • Naturally occurring dominant resistancemutations to hepatitis C virus protease and polymerase inhibitors in treatment-nä?ve patients
    • T. Kuntzen, J. Timm, A. Berical et al., "Naturally occurring dominant resistancemutations to hepatitis C virus protease and polymerase inhibitors in treatment-nä?ve patients, " Hepatology, vol. 48, no. 6, pp. 1769-1778, 2008.
    • (2008) Hepatology , vol.48 , Issue.6 , pp. 1769-1778
    • Kuntzen, T.1    Timm, J.2    Berical, A.3
  • 143
    • 84976260940 scopus 로고    scopus 로고
    • Clinical implications of detectable baseline hepatitis C virus-genotype 1 NS3/4Aprotease variants on the efficacy of boceprevir combined with peginterferon/ribavirin
    • J. A. Howe, J. Long, S. Black et al., "Clinical implications of detectable baseline hepatitis C virus-genotype 1 NS3/4Aprotease variants on the efficacy of boceprevir combined with peginterferon/ribavirin, " Open Forum Infectious Diseases, vol. 1, no. 2, 2014.
    • (2014) Open Forum Infectious Diseases , vol.1 , Issue.2
    • Howe, J.A.1    Long, J.2    Black, S.3
  • 144
    • 84941917709 scopus 로고    scopus 로고
    • Hepatitis C virus drug resistance-associated substitutions: State of the art summary
    • E. Lontok, P. Harrington, A. Howe et al., "Hepatitis C virus drug resistance-associated substitutions: state of the art summary, " Hepatology, vol. 62, no. 5, pp. 1623-1632, 2015.
    • (2015) Hepatology , vol.62 , Issue.5 , pp. 1623-1632
    • Lontok, E.1    Harrington, P.2    Howe, A.3
  • 145
    • 84946409452 scopus 로고    scopus 로고
    • HCVNS3 quasispecies in liver and plasma and dynamics of telaprevir-resistant variants in breakthrough patients assessed by UDPS: A Case Study
    • B. Bartolini, M. Selleri, A. R. Garbuglia et al., "HCVNS3 quasispecies in liver and plasma and dynamics of telaprevir-resistant variants in breakthrough patients assessed by UDPS: A Case Study, " Journal of Clinical Virology, vol. 72, pp. 60-65, 2015.
    • (2015) Journal of Clinical Virology , vol.72 , pp. 60-65
    • Bartolini, B.1    Selleri, M.2    Garbuglia, A.R.3
  • 146
    • 84945466065 scopus 로고    scopus 로고
    • Detection of the NS3 Q80K polymorphism by Sanger and deep sequencing in hepatitis C virus genotype 1a strains in the UK
    • A. Beloukas, S. King, K. Childs et al., "Detection of the NS3 Q80K polymorphism by Sanger and deep sequencing in hepatitis C virus genotype 1a strains in the UK, " Clinical Microbiology and Infection, vol. 21, no. 11, pp. 1033-1039, 2015.
    • (2015) Clinical Microbiology and Infection , vol.21 , Issue.11 , pp. 1033-1039
    • Beloukas, A.1    King, S.2    Childs, K.3
  • 147
    • 84922981045 scopus 로고    scopus 로고
    • Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy
    • L. Boglione, A. De Nicolò, C. S. Cardellino et al., "Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy, " Clinical Microbiology and Infection, vol. 21, no. 2, pp. 205. e1-205. e3, 2015.
    • (2015) Clinical Microbiology and Infection , vol.21 , Issue.2 , pp. 205e1-205e3
    • Boglione, L.1    De Nicolò, A.2    Cardellino, C.S.3
  • 148
    • 80055075318 scopus 로고    scopus 로고
    • NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5
    • S. Vallet, F. Viron, C. Henquell et al., "NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5, " Antiviral Therapy, vol. 16, no. 7, pp. 1093-1102, 2011.
    • (2011) Antiviral Therapy , vol.16 , Issue.7 , pp. 1093-1102
    • Vallet, S.1    Viron, F.2    Henquell, C.3
  • 149
    • 65449157987 scopus 로고    scopus 로고
    • Hepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapy
    • S. Gaudieri, A. Rauch, K. Pfafferott et al., "Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy, " Hepatology, vol. 49, no. 4, pp. 1069-1082, 2009.
    • (2009) Hepatology , vol.49 , Issue.4 , pp. 1069-1082
    • Gaudieri, S.1    Rauch, A.2    Pfafferott, K.3
  • 150
    • 84878116773 scopus 로고    scopus 로고
    • Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors inHepatitis C virus genotypes 1a, 2b and 3a
    • N. Palanisamy, A. Danielsson, C. Kokkula et al., "Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors inHepatitis C virus genotypes 1a, 2b and 3a, " Antiviral Research, vol. 99, no. 1, pp. 12-17, 2013.
    • (2013) Antiviral Research , vol.99 , Issue.1 , pp. 12-17
    • Palanisamy, N.1    Danielsson, A.2    Kokkula, C.3
  • 151
    • 84937734901 scopus 로고    scopus 로고
    • Molecular principles behind Boceprevir resistance due to mutations in hepatitis C NS3/4A protease
    • N. Nagpal, S. Goyal, D. Wahi et al., "Molecular principles behind Boceprevir resistance due to mutations in hepatitis C NS3/4A protease, " Gene, vol. 570, no. 1, pp. 115-121, 2015.
    • (2015) Gene , vol.570 , Issue.1 , pp. 115-121
    • Nagpal, N.1    Goyal, S.2    Wahi, D.3
  • 152
    • 84932620949 scopus 로고    scopus 로고
    • Naturally occurring resistance-associated variants of hepatitis C virus protease inhibitors in poor responders to pegylated interferon-ribavirin
    • S. Larrat, S. Vallet, S. David-Tchouda et al., "Naturally occurring resistance-associated variants of hepatitis C virus protease inhibitors in poor responders to pegylated interferon-ribavirin, " Journal of Clinical Microbiology, vol. 53, no. 7, pp. 2195-2202, 2015.
    • (2015) Journal of Clinical Microbiology , vol.53 , Issue.7 , pp. 2195-2202
    • Larrat, S.1    Vallet, S.2    David-Tchouda, S.3
  • 153
    • 84946490901 scopus 로고    scopus 로고
    • Predominance of hepatitis C virus Q80K among NS3 baseline-resistanceassociated amino acid variants in direct-antiviral-agent-nä?ve patients with chronic hepatitis: Single-centre experience
    • T. Ruggiero, A. Proietti, L. Boglione et al., "Predominance of hepatitis C virus Q80K among NS3 baseline-resistanceassociated amino acid variants in direct-antiviral-agent-nä?ve patients with chronic hepatitis: single-centre experience, " Archives of Virology, vol. 160, no. 11, pp. 2881-2885, 2015.
    • (2015) Archives of Virology , vol.160 , Issue.11 , pp. 2881-2885
    • Ruggiero, T.1    Proietti, A.2    Boglione, L.3
  • 154
    • 84890289271 scopus 로고    scopus 로고
    • Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-nä?ve patients
    • S. Paolucci, L. Fiorina, B. Mariani et al., "Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-nä?ve patients, " Virology Journal, vol. 10, article 355, 2013.
    • (2013) Virology Journal , vol.10
    • Paolucci, S.1    Fiorina, L.2    Mariani, B.3
  • 155
    • 84863663083 scopus 로고    scopus 로고
    • HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors
    • V. Cento, C. Mirabelli, R. Salpini et al., "HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors, " PLoS ONE, vol. 7, article e39652, 2012.
    • (2012) PLoS ONE , vol.7
    • Cento, V.1    Mirabelli, C.2    Salpini, R.3
  • 156
    • 84923842585 scopus 로고    scopus 로고
    • Baseline and post-baseline resistance analyses of phase 2/3 studies of ledipasvir/sofosbuvir +/? RBV
    • C. Sarrazin, H. Dvory-Sobol, E. S. Svarovskaia et al., "Baseline and post-baseline resistance analyses of phase 2/3 studies of ledipasvir/sofosbuvir +/? RBV, " Hepatology, vol. 60, no. 1, p. 1128a, 2014.
    • (2014) Hepatology , vol.60 , Issue.1 , pp. 1128a
    • Sarrazin, C.1    Dvory-Sobol, H.2    Svarovskaia, E.S.3
  • 157
    • 84923842285 scopus 로고    scopus 로고
    • Evaluation of the resistance profile of ledipasvir, a nonstructural protein 5A inhibitor, in genotype 1 chronically infected HCV subjects treated with ledipasvircontaining regimens without sofosbuvir
    • K. M. Kitrinos, D. Wyles, H. Dvory-Sobol, A. Worth, B. Han, and D. Brainard, "Evaluation of the resistance profile of ledipasvir, a nonstructural protein 5A inhibitor, in genotype 1 chronically infected HCV subjects treated with ledipasvircontaining regimens without sofosbuvir, " Hepatology, vol. 60, pp. 1143a-1144a, 2014.
    • (2014) Hepatology , vol.60 , pp. 1143a-1144a
    • Kitrinos, K.M.1    Wyles, D.2    Dvory-Sobol, H.3    Worth, A.4    Han, B.5    Brainard, D.6
  • 158
    • 84858415895 scopus 로고    scopus 로고
    • Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor
    • Z. Plaza, V. Soriano, E. Vispo et al., "Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor, " AntiviralTherapy, vol. 17, no. 5, pp. 921-926, 2012.
    • (2012) AntiviralTherapy , vol.17 , Issue.5 , pp. 921-926
    • Plaza, Z.1    Soriano, V.2    Vispo, E.3
  • 159
    • 84946207144 scopus 로고    scopus 로고
    • Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir
    • R. Liu, S. Curry, P. McMonagle et al., "Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir, "AntimicrobialAgents and Chemotherapy, vol. 59, no. 11, pp. 6922-6929, 2015.
    • (2015) AntimicrobialAgents and Chemotherapy , vol.59 , Issue.11 , pp. 6922-6929
    • Liu, R.1    Curry, S.2    McMonagle, P.3
  • 160
    • 84961575132 scopus 로고    scopus 로고
    • Directly acting antivirals against hepatitis C virus: Mechanisms of action and impact of resistant associated variants
    • C. Premoli and A. Aghemo, "Directly acting antivirals against hepatitis C virus: mechanisms of action and impact of resistant associated variants, " Minerva Gastroenterologica e Dietologica, vol. 62, no. 1, pp. 76-87, 2016.
    • (2016) Minerva Gastroenterologica e Dietologica , vol.62 , Issue.1 , pp. 76-87
    • Premoli, C.1    Aghemo, A.2
  • 161
    • 82455192239 scopus 로고    scopus 로고
    • Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: In vitro and in vivo correlations
    • R. A. Fridell, C. Wang, J.-H. Sun et al., "Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations, " Hepatology, vol. 54, no. 6, pp. 1924-1935, 2011.
    • (2011) Hepatology , vol.54 , Issue.6 , pp. 1924-1935
    • Fridell, R.A.1    Wang, C.2    Sun, J.-H.3
  • 162
    • 84862684876 scopus 로고    scopus 로고
    • A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C
    • E. J. Lawitz, D. Gruener, J. M. Hill et al., "A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C, " Journal of Hepatology, vol. 57, no. 1, pp. 24-31, 2012.
    • (2012) Journal of Hepatology , vol.57 , Issue.1 , pp. 24-31
    • Lawitz, E.J.1    Gruener, D.2    Hill, J.M.3
  • 163
    • 84941925149 scopus 로고    scopus 로고
    • Genetic diversity and selective pressure in hepatitis C virus genotypes 1-6: Significance for direct-acting antiviral treatment and drug resistance
    • L. Cuypers, G. Li, P. Libin, S. Piampongsant, A.-M. Vandamme, and K. Theys, "Genetic diversity and selective pressure in hepatitis C virus genotypes 1-6: significance for direct-acting antiviral treatment and drug resistance, " Viruses, vol. 7, no. 9, pp. 5018-5039, 2015.
    • (2015) Viruses , vol.7 , Issue.9 , pp. 5018-5039
    • Cuypers, L.1    Li, G.2    Libin, P.3    Piampongsant, S.4    Vandamme, A.-M.5    Theys, K.6
  • 165
    • 84927926524 scopus 로고    scopus 로고
    • Pooled analysis of resistance in patients treated with ombitasvir/ABT-450/r and dasabuvir with or without ribavirin in Phase 2 and Phase 3 clinical trials
    • P. Krishnan, R. Tripathi, G. Schnell, T. Reisch, J. Beyer, and M. Irvin, "Pooled analysis of resistance in patients treated with ombitasvir/ABT-450/r and dasabuvir with or without ribavirin in Phase 2 and Phase 3 clinical trials, " Hepatology, vol. 60, no. 1, pp. 1134a-1135a, 2014.
    • (2014) Hepatology , vol.60 , Issue.1 , pp. 1134a-1135a
    • Krishnan, P.1    Tripathi, R.2    Schnell, G.3    Reisch, T.4    Beyer, J.5    Irvin, M.6
  • 166
    • 84863156581 scopus 로고    scopus 로고
    • In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A
    • C. Wang, L. Jia, H. Huang et al., "In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A, " Antimicrobial Agents and Chemotherapy, vol. 56, no. 3, pp. 1588-1590, 2012.
    • (2012) Antimicrobial Agents and Chemotherapy , vol.56 , Issue.3 , pp. 1588-1590
    • Wang, C.1    Jia, L.2    Huang, H.3
  • 167
    • 84875804486 scopus 로고    scopus 로고
    • Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors
    • D. Hernandez, N. Zhou, J. Ueland, A. Monikowski, and F. McPhee, "Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors, " Journal of Clinical Virology, vol. 57, no. 1, pp. 13-18, 2013.
    • (2013) Journal of Clinical Virology , vol.57 , Issue.1 , pp. 13-18
    • Hernandez, D.1    Zhou, N.2    Ueland, J.3    Monikowski, A.4    McPhee, F.5
  • 168
    • 84862560600 scopus 로고    scopus 로고
    • Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir
    • F. McPhee, J. Friborg, S. Levine et al., "Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir, " AntimicrobialAgents and Chemotherapy, vol. 56, no. 7, pp. 3670-3681, 2012.
    • (2012) AntimicrobialAgents and Chemotherapy , vol.56 , Issue.7 , pp. 3670-3681
    • McPhee, F.1    Friborg, J.2    Levine, S.3
  • 169
    • 84880931245 scopus 로고    scopus 로고
    • Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir
    • Y. Karino, J. Toyota, K. Ikeda et al., "Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir, " Journal of Hepatology, vol. 58, no. 4, pp. 646-654, 2013.
    • (2013) Journal of Hepatology , vol.58 , Issue.4 , pp. 646-654
    • Karino, Y.1    Toyota, J.2    Ikeda, K.3
  • 170
    • 84924241449 scopus 로고    scopus 로고
    • Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b
    • F. McPhee, D. Hernandez, N. Zhou et al., "Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b, " Antiviral Therapy, vol. 19, no. 5, pp. 479-490, 2014.
    • (2014) Antiviral Therapy , vol.19 , Issue.5 , pp. 479-490
    • McPhee, F.1    Hernandez, D.2    Zhou, N.3
  • 171
    • 84939174987 scopus 로고    scopus 로고
    • Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to interleukin-28B genotype and are sensitive to interferonbased therapy
    • J. Itakura, M. Kurosaki, H. Takada et al., "Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to interleukin-28B genotype and are sensitive to interferonbased therapy, " Hepatology Research, vol. 45, no. 10, pp. E115-E121, 2015.
    • (2015) Hepatology Research , vol.45 , Issue.10 , pp. E115-E121
    • Itakura, J.1    Kurosaki, M.2    Takada, H.3
  • 172
    • 84946488527 scopus 로고    scopus 로고
    • Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice
    • Y. Kai, H. Hikita, T. Tatsumi et al., "Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice, " Journal of Gastroenterology, vol. 50, no. 11, pp. 1145-1151, 2015.
    • (2015) Journal of Gastroenterology , vol.50 , Issue.11 , pp. 1145-1151
    • Kai, Y.1    Hikita, H.2    Tatsumi, T.3
  • 173
    • 84906087908 scopus 로고    scopus 로고
    • Comparison of daclatasvir resistance barriers on NS5A fromhepatitisCvirus genotypes 1 to 6: Implications for cross-genotype activity
    • C. Wang, L. Jia, D. R. O'Boyle II et al., "Comparison of daclatasvir resistance barriers on NS5A fromhepatitisCvirus genotypes 1 to 6: Implications for cross-genotype activity, " Antimicrobial Agents and Chemotherapy, vol. 58, no. 9, pp. 5155-5163, 2014.
    • (2014) Antimicrobial Agents and Chemotherapy , vol.58 , Issue.9 , pp. 5155-5163
    • Wang, C.1    Jia, L.2    O'Boyle, D.R.3
  • 174
    • 84961742925 scopus 로고    scopus 로고
    • Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden
    • I. Lindström, M. Kjellin, N. Palanisamy et al., "Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden, " InfectiousDiseases, vol. 47, no. 8, pp. 555-562, 2015.
    • (2015) InfectiousDiseases , vol.47 , Issue.8 , pp. 555-562
    • Lindström, I.1    Kjellin, M.2    Palanisamy, N.3
  • 175
    • 84901036125 scopus 로고    scopus 로고
    • ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis
    • F. Poordad, C. Hezode, R. Trinh et al., "ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis, " The New England Journal ofMedicine, vol. 370, no. 21, pp. 1973-1982, 2014.
    • (2014) The New England Journal OfMedicine , vol.370 , Issue.21 , pp. 1973-1982
    • Poordad, F.1    Hezode, C.2    Trinh, R.3
  • 176
    • 84921276609 scopus 로고    scopus 로고
    • Infrequent development of resistance in genotype 1-6 hepatitis c virusinfected subjects treated with sofosbuvir in phase 2 and 3 clinical trials
    • E. S. Svarovskaia, H. Dvory Sobol, N. Parkin et al., "Infrequent development of resistance in genotype 1-6 hepatitis c virusinfected subjects treated with sofosbuvir in phase 2 and 3 clinical trials, " Clinical Infectious Diseases, vol. 59, no. 12, pp. 1666-1674, 2014.
    • (2014) Clinical Infectious Diseases , vol.59 , Issue.12 , pp. 1666-1674
    • Svarovskaia, E.S.1    Dvory Sobol, H.2    Parkin, N.3
  • 177
  • 178
    • 84922879130 scopus 로고    scopus 로고
    • Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation
    • M. Charlton, E. Gane, M. P. Manns et al., "Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation, "Gastroenterology, vol. 148, no. 1, pp. 108-117, 2015.
    • (2015) Gastroenterology , vol.148 , Issue.1 , pp. 108-117
    • Charlton, M.1    Gane, E.2    Manns, M.P.3
  • 179
    • 84894271490 scopus 로고    scopus 로고
    • In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir
    • X. Tong, S. Le Pogam, L. Li et al., "In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir, " Journal of Infectious Diseases, vol. 209, no. 5, pp. 668-675, 2014.
    • (2014) Journal of Infectious Diseases , vol.209 , Issue.5 , pp. 668-675
    • Tong, X.1    Le Pogam, S.2    Li, L.3
  • 181
    • 84898645159 scopus 로고    scopus 로고
    • Hepatitis c virus genetic variability and the presence of ns5b resistance-Associated mutations as natural polymorphisms in selected genotypes could affect the response to ns5b inhibitors
    • V. C. Di Maio, V. Cento, C. Mirabelli et al., "Hepatitis c virus genetic variability and the presence of ns5b resistance-Associated mutations as natural polymorphisms in selected genotypes could affect the response to ns5b inhibitors, " Antimicrobial Agents and Chemotherapy, vol. 58, no. 5, pp. 2781-2797, 2014.
    • (2014) Antimicrobial Agents and Chemotherapy , vol.58 , Issue.5 , pp. 2781-2797
    • Di Maio, V.C.1    Cento, V.2    Mirabelli, C.3
  • 182
    • 84913539309 scopus 로고    scopus 로고
    • P1230 lack of impact of baseline resistance-associated variants (RAVS) on treatment outcome in the aviator study with ABT-450/R, ABT-333 and ABT-267, +/-Ribavirin
    • P. Krishnan, R. Tripathi, M. Irvin et al., "P1230 lack of impact of baseline resistance-associated variants (RAVS) on treatment outcome in the aviator study with ABT-450/R, ABT-333 AND ABT-267, +/-Ribavirin, " Journal of Hepatology, vol. 60, no. 1, article S498, 2014.
    • (2014) Journal of Hepatology , vol.60 , Issue.1
    • Krishnan, P.1    Tripathi, R.2    Irvin, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.